Loading market movers...

Teriflunomide 14 MG Oral Tablet [Aubagio]

Phase 3

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Multiple Sclerosis

TEVAocrelizumab

TEVAocrelizumab biosimilar

View Full Landscape

Drug Information

Target Indication

Multiple Sclerosis

Clinical Trial

Last updated: 8/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/26/2013

Aubagio

AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

zolpidem-MR (SL800750)Phase 3

Sleep Initiation and Maintenance Disorders

efanesoctocog alfa (BIVV001)Phase 3

Hemophilia A

DuvakitugPhase 3

Ulcerative Colitis

xaliproden (SR57746A)Phase 3

Alzheimer Disease

A/H1N1 pandemic influenza vaccine (non- adjuvanted)Phase 3

Influenza

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts